Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

pemphigus News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

A global phase III trial demonstrates the efficacy and safety of subcutaneous efgartigimod combined with prednisone in treating moderate-to-severe pemphigus. This randomized controlled study provides critical insights into potential new treatment options for this rare autoimmune disease.

A case report highlights the successful treatment of pemphigus erythematosus using the JAK1 inhibitor upadacitinib. This study contributes to the growing body of literature on targeted therapies for autoimmune skin diseases.

A new randomized controlled trial protocol aims to evaluate the effects of an intelligent multimodal symptom assessment and response system in patients with pemphigus vulgaris. This study could provide insights into improving patient management for this rare autoimmune disease.

A recent study identifies genetic and immunological factors influencing pemphigus vulgaris, focusing on HLA-DRB1 and FCGR2B variants. This integrative analysis enhances understanding of the disease's underlying mechanisms.

A case report highlights the occurrence of postsurgical pemphigus vulgaris following thyroidectomy, contributing to the understanding of this rare autoimmune condition. The review of literature provides insights into potential triggers and management strategies.

A recent cross-sectional survey highlights the significant family burden associated with pemphigus, emphasizing the need for improved support systems for affected families. The findings contribute to understanding the broader impact of this rare autoimmune disease.

A recent case report highlights ibuprofen as a potential trigger for pemphigus vulgaris, a rare autoimmune blistering disorder. This finding may prompt further investigation into drug-induced cases of this disease.

A case-control study in Liguria, Italy, identifies pesticide exposure as a potential risk factor for pemphigus vulgaris. This research adds to the understanding of environmental influences on this rare autoimmune disease.

Recent research highlights the need for optimized local treatment strategies in pemphigus and pemphigoid, addressing current evidence and unmet needs in patient care. This study emphasizes the importance of tailored approaches to improve outcomes for affected individuals.

Not rare diseases news,news about your rare disease.